argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
13 mei 2015 - 18:10
Statutaire naam
argenx SE
Titel
arGEN-X announces results of Annual General Meeting 2015
Bericht
Breda, the Netherlands / Ghent, Belgium, 13 May 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that all resolutions presented at the Company's Annual General Meeting were duly passed at the meeting, which was held today at 09:00 CET.
Gerelateerde downloads
Datum laatste update: 01 september 2024